Asia is rewriting healthcare digitally, and it’s doing it where the physical infrastructure is thinnest. In China, JD Health alone generated around $8 billion in revenue and handles nearly half a million online consultations a day. In India, the public Ayushman Bharat Digital Mission has linked over a billion health records — the largest public digital-health infrastructure on earth by population reach. And across the Asia-Pacific, 49% of digital-health venture products are mobile apps versus just 32% in the West (Galen Growth) — a structurally mobile-first sector in a region where rural areas can have one doctor per 10,000 people. This is the leapfrog: in markets that never built enough clinics, healthcare went straight to the phone.
How big is Asia’s digital health market?
Large and growing fast, though the definitions matter. Research-firm estimates put the Asia-Pacific digital-health market around $72 billion in 2024, forecast to grow at well over 20% a year (Grand View Research) — but treat these vendor figures as directional, not gospel. The cleaner signal is venture funding: Asia-Pacific healthtech startups raised about $2 billion across 244 deals in 2024, then recovered 14% to roughly $2.4 billion in 2025 — outpacing North America’s growth (Galen Growth).
Don’t confuse the two. The ~$72 billion is total market revenue; the ~$2 billion is annual venture capital into startups. Conflating market size with funding is the most common error in reading this sector, and they tell different stories — one of scale, one of investor appetite returning after a downturn.
How did Asia leapfrog to digital health?
By necessity. In markets with too few doctors and too little hospital capacity, telemedicine didn’t disrupt an existing system so much as reach people the system never could. The WHO recommends one doctor per 1,000 people; in rural parts of Asia that thins to one per 10,000. Into that gap came mobile-first health apps — teleconsultation, e-pharmacy, remote diagnostics — accelerated enormously by COVID. The result is a sector built around the smartphone from the start, which is why nearly half of Asian digital-health products are mobile apps versus a third in the West.
The revenue engine, tellingly, isn’t consultation — it’s e-pharmacy. The biggest digital-health companies in Asia by revenue are medicine marketplaces: JD Health, Alibaba Health and India’s Tata 1mg all make most of their money selling drugs, with telemedicine as the on-ramp. Healthcare in Asia monetises through the pharmacy.
Who are the biggest healthtech companies in China?
China has the scale leaders. JD Health, China’s largest internet healthcare platform, posted 2024 revenue of 58.16 billion yuan (about $8 billion), up 8.6%, with 183.6 million annual active users and over 490,000 daily online consultations (JD Health). Alibaba Health (AliHealth) is the other giant, with roughly 85% of its revenue from pharmaceutical direct sales.
The more revealing story is Ping An Good Doctor, which reported its first-ever full-year profit in 2024, then grew profit 366% in 2025 — completing a pivot from a loss-making consumer app into a B2B corporate-health and insurance-enablement business. China’s healthtech giants reached scale years ago; the 2026 story is them finally reaching profitability, by selling to employers and insurers rather than chasing individual app users.
What is India’s digital health stack?
India built something no other country has at this scale: a public digital-health infrastructure. The Ayushman Bharat Digital Mission has issued over 900 million digital health IDs and linked more than a billion health records — open, government-run rails that private apps plug into (National Health Authority). It’s the health-sector equivalent of UPI in payments: a public good that lets a thousand private services interoperate.
The private side has been more turbulent. PharmEasy collapsed from a $5.6 billion peak valuation in 2021 to roughly $710 million in a 2024 rights issue — a ~90% haircut — the sector’s cautionary tale. But Practo, Tata 1mg and Apollo 24/7 continue to scale, e-pharmacy again the durable model. India shows both halves of Asian healthtech: a world-leading public stack, and a private market that overheated and reset.
Who leads healthtech in Southeast Asia?
Southeast Asia is the region’s clearest leapfrog story, and Indonesia is its hub. Halodoc, the Indonesian telemedicine leader, connects more than 20 million monthly users to doctors, pharmacies and lab tests through a single app, backed by a $100 million round led by Astra — a textbook case of digital health reaching a vast, geographically dispersed population that physical clinics never could. Its rival Alodokter plays the same game at scale, and the model fits a country of 17,000 islands better than any amount of hospital-building could.
Beyond Indonesia, Singapore’s Doctor Anywhere operates telehealth across multiple Southeast Asian markets, and the region’s healthtech leans heavily on the same e-pharmacy-plus-teleconsult formula that works elsewhere in Asia — with the added twist that super-apps like Grab and Gojek have folded health services into their ecosystems, putting a doctor a tap away inside apps people already use daily. Southeast Asian healthtech is younger and smaller than China’s or India’s, but it’s growing fast precisely because the gap it fills — access for the underserved — is so wide. For the payment rails these services run on, see our Asia digital payments tracker.
What about Japan and Korea?
The two markets sit at the opposite end of the spectrum from the leapfrog story — they have world-class physical healthcare and ageing populations, so their healthtech is about efficiency and longevity, not access. Japan, the world’s oldest major society with nearly 30% of its population over 65, is effectively a national laboratory for elder-care technology: nursing robots, remote patient monitoring, and AI tools to stretch a shrinking care workforce across a growing elderly population. Its strength in medical devices and diagnostics imaging is decades deep, even if its consumer digital-health adoption has lagged behind China’s app-first model.
South Korea punches well above its size in medical AI and digital diagnostics. Backed by a near-universal, heavily digitised national health-insurance system and strong AI research, Korean firms are prominent in AI medical imaging, biomarker diagnostics and mental-health tech, and the country has been an early adopter of telemedicine after pandemic-era rules loosened. Where China’s healthtech is built on scale and India’s on a public data stack, Korea’s edge is clinical-grade AI and Japan’s is the hard problem of ageing — between them, North Asia covers the parts of digital health the leapfrog markets don’t.
How is AI used in Asian healthcare?
Diagnostics is where Asia leads, and China leads Asia. China’s regulator had approved 154 AI-based medical devices by 2025 — 80% of them in the highest risk class, and 69% in radiology and medical imaging (JMIR). That’s a genuine lead in clinical-imaging deployment, even if the US FDA has cleared more AI devices overall across all categories. AI triage, medical-image analysis and drug discovery are all advancing fast across the region, with Chinese and Indian companies prominent.
The fit is natural: in a sector short of specialists, AI that can read a scan or triage a symptom extends scarce expertise across far more patients. It’s the same leapfrog logic that built Asian digital health in the first place, applied to the next layer. For the broader regional AI picture, see our Asia AI market breakdown.
Frequently asked questions
How big is the digital health market in Asia?
Research-firm estimates put the Asia-Pacific digital-health market around $72 billion in 2024, growing at over 20% a year (Grand View Research). Separately, Asian healthtech startups raised about $2 billion in venture funding in 2024, recovering to ~$2.4 billion in 2025 (Galen Growth) — market size and funding are distinct metrics.
What is the biggest healthtech company in Asia?
By revenue, JD Health — China’s largest internet healthcare platform — generated about $8 billion (58.16 billion yuan) in 2024 with 183.6 million annual users and over 490,000 daily online consultations. Most of its revenue, like its peers’, comes from e-pharmacy.
Why is telemedicine so big in Asia?
Because it reaches people the physical system can’t. With doctor shortages as severe as one per 10,000 in rural areas, mobile-first health apps filled a gap rather than disrupting an existing system — making Asian digital health structurally mobile-first (49% of products are apps versus 32% in the West).
What is India’s Ayushman Bharat Digital Mission?
A public digital-health infrastructure that has issued over 900 million digital health IDs and linked more than a billion health records — the world’s largest by population reach. It provides open, government-run rails that private health apps connect to, similar to how UPI works in payments.
Does Asia lead in medical AI?
In clinical imaging, yes. China’s regulator had approved 154 AI-based medical devices by 2025, 69% of them in radiology and imaging — a lead in deployment, though the US has cleared more AI devices overall across all categories.
—
Discover more from Digital in Asia
Subscribe to get the latest posts sent to your email.
